With global orphan drug sales rising almost 10% a year from 2005 to 2011, twice as fast as the market as a whole, the current austerity conscious governments are applying the same pricing scrutiny to orphan drugs. But what are the HTA considerations for orphan drugs and future pricing and cost containment to establish and maintain a level that's going to be sustainable?
In this ebook, we present some thoughts on HTA for orphan drugs.
Download this ebook and learn about:
- Rare diseases: the facts
- Market access challenges for orphan drugs
- Challenges with endpoint for rare diseases
- Pricing scrutiny
- UK reforms
Want to learn more about HTA for orphan drugs? Join us at HTA World Europe 2013 conference, where we will bring together top HTA authorities and industry leaders to discuss the future of orphan drug market access.